Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) Given Average Recommendation of “Hold” by Brokerages
Shares of Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) have received a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $14.80.
Separately, Zacks Investment Research lowered shares of Aegerion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 25th.
In other Aegerion Pharmaceuticals news, major shareholder Healthcare Master Fun Broadfin bought 75,000 shares of Aegerion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 13th. The shares were acquired at an average price of $1.75 per share, for a total transaction of $131,250.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.60% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Sarissa Capital Management LP raised its position in shares of Aegerion Pharmaceuticals by 2.7% in the second quarter. Sarissa Capital Management LP now owns 2,649,000 shares of the biopharmaceutical company’s stock worth $3,947,000 after buying an additional 69,000 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Aegerion Pharmaceuticals during the second quarter worth approximately $142,000. Jefferies Group LLC raised its position in shares of Aegerion Pharmaceuticals by 149.9% in the second quarter. Jefferies Group LLC now owns 745,150 shares of the biopharmaceutical company’s stock worth $1,110,000 after buying an additional 447,027 shares in the last quarter. Spark Investment Management LLC raised its position in shares of Aegerion Pharmaceuticals by 10.1% in the second quarter. Spark Investment Management LLC now owns 586,400 shares of the biopharmaceutical company’s stock worth $873,000 after buying an additional 53,600 shares in the last quarter. Finally, Ancora Advisors LLC purchased a new position in shares of Aegerion Pharmaceuticals during the second quarter worth approximately $114,000. Hedge funds and other institutional investors own 87.60% of the company’s stock.
Aegerion Pharmaceuticals (NASDAQ:AEGR) traded up 4.36% on Wednesday, reaching $2.87. The company had a trading volume of 298,466 shares. The stock’s market capitalization is $84.71 million. Aegerion Pharmaceuticals has a 52-week low of $1.23 and a 52-week high of $16.63. The stock has a 50 day moving average price of $1.98 and a 200 day moving average price of $2.12.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.34. The firm earned $44.50 million during the quarter, compared to analysts’ expectations of $35.50 million. Aegerion Pharmaceuticals had a negative return on equity of 128.77% and a negative net margin of 80.76%. Analysts expect that Aegerion Pharmaceuticals will post ($3.44) EPS for the current year.
Aegerion Pharmaceuticals Company Profile
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Stock Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.